The day and time referred to above shall constitute the Record Date. Only persons who are shareholders on
the Record Date are entitled to attend and vote at the general meeting.
A certificate is delivered to the shareholder by the settlement institution or
certified account holder which certifies the number of dematerialised shares registered in its accounts under the name of the shareholder on the Record Date, for which the shareholder has expressed its intention to participate in the general
meeting.
The shareholder indicates his intention to participate in the general meeting by 16 December 2023 at the latest. This must be done by email
to investors@celyad.com, or by mail marked for the attention of Celyad Oncology SA, Mrs. An Phan, Head of Legal, Rue André Dumont 9, B-1435 Mont-Saint-Guibert.
The holders of warrants have the right to attend the general meeting, subject to them fulfilling the shareholders admission conditions.
Right to include items on the agenda and to submit proposals for decisions
In accordance with Article 7:130 of the Companies and Associations Code, one or more shareholders holding together at least 3% of the share capital may request
the inclusion of items on the agenda to be addressed at the general meeting and request the submission of decisions proposals concerning items to be addressed or included on the agenda.
The shareholder or shareholders exercising this right must, in order for their request to be examined at the general meeting, satisfy the following two
conditions:
|
|
|
prove that they hold the abovementioned required percentage on the date of their request (either by way of a
certificate mentioning the registration of the corresponding shares on the Companys share register, or by way of an attest of a settlement institution or a certified account holder setting out the number of corresponding dematerialised shares
registered in its accounts under the name of the shareholder); and |
|
|
|
still be a shareholder for up to 3% of the Companys share capital on the Record Date.
|
Items to be included on this agenda and/or decisions proposals must be sent to the Company on 30 November 2023 at the
latest by email to investors@celyad.com, or by mail marked for the attention of Celyad Oncology SA, Mrs. An Phan, Head of Legal, Rue André Dumont 9, B-1435 Mont-Saint-Guibert.
The Company will acknowledge receipt of the requests sent by email or by mail to the address indicated by the shareholder within 48 hours after receipt.
The revised agenda will be published on 7 December 2023 at the latest (on the Companys website at the address www.celyad.com, in the Belgian
Official Gazette and in the press) if one or more requests to include new items or proposals for decisions on the agenda have been received within the aforementioned deadline.
Further information relating to the abovementioned rights and the modalities for exercising them are available on the Companys website
(www.celyad.com).
Right to ask questions
Shareholders may ask questions exclusively in writing before the meeting, concerning the report of the Board of Directors or the agenda of the meeting. The
Company will answer the questions during the meeting.
The questions can be sent prior to the general meeting by email to the address
investors@celyad.com or by mail marked for the attention of Celyad Oncology SA, Mrs. An Phan, Head of Legal, Rue André Dumont 9, B-1435 Mont-Saint-Guibert.
Those questions must be received by the Company on 16 December 2023 at 17h00 (CET) at the latest.
3